Omnicell (OMCL) – Analysts’ Recent Ratings Changes

Omnicell (NASDAQ: OMCL) has recently received a number of price target changes and ratings updates:

• 2/4/2026 – Omnicell was upgraded by analysts at Bank of America Corporation from a “neutral” rating to a “buy” rating. They now have a $70.00 price target on the stock.
• 2/2/2026 – Omnicell had its price target raised by analysts at Benchmark Co. from $50.00 to $60.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Omnicell had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 1/16/2026 – Omnicell was given a new $53.00 price target on by analysts at UBS Group AG.
• 1/7/2026 – Omnicell was upgraded by analysts at KeyCorp from a “sector weight” rating to an “overweight” rating. They now have a $60.00 price target on the stock.
• 1/5/2026 – Omnicell had its price target raised by analysts at Wells Fargo & Company from $43.00 to $52.00. They now have an “overweight” rating on the stock.
• 12/9/2025 – Omnicell was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 12/9/2025 – Omnicell had its price target raised by analysts at Benchmark Co. from $45.00 to $50.00. They now have a “buy” rating on the stock.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president owned 91,674 shares of the company’s stock, valued at $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.52% of the company’s stock.

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.